WeightWatchers has announced a strategic partnership with CheqUp, a provider of GLP-1 weight-loss medications such as Wegovy and Mounjaro, marking a significant shift away from its traditional dieting model. The move comes weeks after the company filed for Chapter 11 bankruptcy protection in the US, as demand for its points-based programme has declined amid the rising popularity of anti-obesity injections.
Under the partnership, CheqUp members will gain access to a WeightWatchers app specifically designed for individuals on weight-loss medication. The app provides expert guidance on food recommendations to minimise side effects like nausea while supporting healthy weight loss. The companies stated that the collaboration aims to help patients achieve better results than with medication alone, combining clinical support with behavioural coaching.
WeightWatchers, which rebranded as WW in 2018, has seen its shares lose 82% of their value this year. Former top shareholder Oprah Winfrey left the company in February last year after revealing her weight loss was due to anti-obesity drugs. The partnership with CheqUp reflects the growing demand for GLP-1 medications in the UK, as obesity experts call for wider NHS use of such treatments.
Scott Honken, chief commercial officer at WeightWatchers, noted that data from the US shows members on obesity medications who also participate in the company's lifestyle programme lose 11% more weight on average than those using medication alone. James Hunt, deputy chief executive of CheqUp, said the addition of WeightWatchers' programme will enhance patients' ability to achieve sustainable weight loss.
